

## Financial Tear Sheet

Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company's lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.

### Stock Quote


ADRO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	<b>\$6.83</b>
Change (%)	<b>+0.44 (6.89%)</b>
Volume	403,389

Data as of October 16, 2018 4:00 p.m. ET

Minimum 20 minute delay

[Refresh quote](#)

### Stock Chart



## Press Releases

October 01, 2018

[Aduro Biotech Announces Four Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer \(SITC\) Annual Meeting](#)

September 25, 2018

[Aduro Biotech to Present at Two Investor Conferences in October](#)

## Events & Presentations

There are currently no events scheduled.

Data Provided by Thomson Reuters